We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
Fig. 2

Fig. 2. GDF-15 groups and mortality in the general population. From: Association of Growth Differentiation Factor-15 with Coronary Atherosclerosis and Mortality in a Young, Multiethnic Population: Observations from the Dallas Heart Study.

(A), All-cause mortality. (B), Cardiovascular mortality. Unadjusted hazard ratios calculated for GDF-15 groups compared with GDF-15 <1200 ng/L, from Cox proportional hazards models for all-cause death (120/2754) and cardiovascular death (48/2754) in the general population.

Anand Rohatgi, et al. Clin Chem. 2012 January;58(1):172-182.
2.
Fig. 3

Fig. 3. GDF-15 groups and mortality in those without cardiovascular disease. From: Association of Growth Differentiation Factor-15 with Coronary Atherosclerosis and Mortality in a Young, Multiethnic Population: Observations from the Dallas Heart Study.

(A), All-cause mortality. (B), Cardiovascular mortality. Unadjusted hazard ratios calculated for GDF-15 groups compared with GDF-15 <1200 ng/L, from Cox proportional hazards models for all-cause death (77/2288) and cardiovascular death (26/2288) in those without cardiovascular disease.

Anand Rohatgi, et al. Clin Chem. 2012 January;58(1):172-182.
3.
Fig. 1

Fig. 1. Prevalent coronary calcium by GDF-15 groups. From: Association of Growth Differentiation Factor-15 with Coronary Atherosclerosis and Mortality in a Young, Multiethnic Population: Observations from the Dallas Heart Study.

Adjusted odds ratios calculated for GDF-15 groups compared with GDF-15 <1200 ng/L, from logistic regression models for CAC >10 and CAC ≥ 100 in the general population and in those without cardiovascular disease, adjusting for age, sex, hypertension, diabetes, smoking, hypercholesterolemia, low HDL cholesterol, BMI, black or Hispanic race, eGFR, and LV mass/body surface area. Model for general population additionally adjusted for history of cardiovascular disease. CVD, self-reported history of MI, CHF, or stroke or evidence of median sternotomy or coronary stent on EBCT.

Anand Rohatgi, et al. Clin Chem. 2012 January;58(1):172-182.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk